Literature DB >> 15750935

Colonic atresia without mesenteric vascular occlusion. The role of the fibroblast growth factor 10 signaling pathway.

Timothy J Fairbanks1, Robert C Kanard, Pierre M Del Moral, Fred G Sala, Stijn P De Langhe, Chrissy A Lopez, Jacqueline M Veltmaat, David Warburton, Kathryn D Anderson, Saverio Bellusci, R Cartland Burns.   

Abstract

BACKGROUND/
PURPOSE: Colonic atresia occurs in 1:20,000 live births, offering a neonatal surgical challenge. Prenatal expression of fibroblast growth factor 10 (Fgf10), acting through fibroblast growth factor receptor 2b (Fgfr2b), is critical to the normal development of the colon. Invalidation of the Fgf10 pathway results in colonic atresia, inherited in an autosomal recessive pattern. Classically, disturbance of the mesenteric vasculature has been thought to cause many forms of intestinal atresia. The purpose of this study was to evaluate the role of vascular occlusion in the pathogenesis of colonic atresia.
METHODS: Wild type (Wt), Fgf10(-/-), and Fgfr2b(-/-) mutant mouse embryos were harvested from timed pregnant mothers. Immediately following harvest, filtered India ink was infused via intracardiac microinjection. The gastrointestinal tract was dissected, and photomicrographs of the mesenteric arterial anatomy were taken at key developmental time points.
RESULTS: Photomicrographs after India ink microinjections demonstrate normal, patent mesenteric cascades to the atretic colon at the time points corresponding to the failure of colonic development in the Fgf10(-/-) and Fgfr2b(-/-) mutants. The mesenteric arterial anatomy of the colon demonstrates no difference between the Wt and mutant colonic atresia.
CONCLUSIONS: The absence of embryonic expression of Fgf10 or its receptor Fgfr2b results in colonic atresia in mice. India ink microinjection is a direct measure of mesenteric arterial patency. Colonic atresia in the Fgf10(-/-) and Fgfr2b(-/-) mutants occurs despite normal mesenteric vascular development. Thus the atresia is not the result of a mesenteric vascular occlusion. The patent colonic mesentery of the Fgf10(-/-) and Fgfr2b(-/-) mutants challenges an accepted pathogenesis of intestinal atresia. Although colonic atresia can occur as a result of vascular occlusion, new evidence exists to suggest that a genetic mechanism may play a role in the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750935     DOI: 10.1016/j.jpedsurg.2004.10.023

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  15 in total

1.  Fibroblast growth factor 10 alters the balance between goblet and Paneth cells in the adult mouse small intestine.

Authors:  Denise Al Alam; Soula Danopoulos; Kathy Schall; Frederic G Sala; Dana Almohazey; G Esteban Fernandez; Senta Georgia; Mark R Frey; Henri R Ford; Tracy Grikscheit; Saverio Bellusci
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-02-26       Impact factor: 4.052

2.  Formation of duodenal atresias in fibroblast growth factor receptor 2IIIb-/- mouse embryos occurs in the absence of an endodermal plug.

Authors:  Robert A Botham; Marta Franco; Amy L Reeder; Anastasia Lopukhin; Kohei Shiota; Shigehito Yamada; Peter F Nichol
Journal:  J Pediatr Surg       Date:  2012-07       Impact factor: 2.545

3.  Haploinsufficiency of retinaldehyde dehydrogenase 2 decreases the severity and incidence of duodenal atresia in the fibroblast growth factor receptor 2IIIb-/- mouse model.

Authors:  Amy L Reeder; Robert A Botham; Krzysztof M Zaremba; Peter F Nichol
Journal:  Surgery       Date:  2012-10       Impact factor: 3.982

4.  A more efficient method to generate null mutants using Hprt-Cre with floxed alleles.

Authors:  Peter F Nichol; Robert Botham; Yukio Saijoh; Amy L Reeder; Krzyztoff M Zaremba
Journal:  J Pediatr Surg       Date:  2011-09       Impact factor: 2.545

5.  Exogenous Sonic hedgehog protein does not rescue cultured intestine from atresia formation.

Authors:  Amy L Reeder; Krzysztof M Zaremba; Rebeca M Liebl; Anna Kowalkowski; Peter F Nichol
Journal:  J Surg Res       Date:  2013-12-07       Impact factor: 2.192

6.  Exome sequencing of family trios from the National Birth Defects Prevention Study: Tapping into a rich resource of genetic and environmental data.

Authors:  Mary M Jenkins; Lynn M Almli; Faith Pangilinan; Jessica X Chong; Elizabeth E Blue; Stuart K Shapira; Janson White; Daniel McGoldrick; Joshua D Smith; James C Mullikin; Christopher J Bean; Wendy N Nembhard; Xiang-Yang Lou; Gary M Shaw; Paul A Romitti; Kim Keppler-Noreuil; Mahsa M Yazdy; Denise M Kay; Tonia C Carter; Andrew F Olshan; Kristin J Moore; Nanette Nascone-Yoder; Richard H Finnell; Philip J Lupo; Marcia L Feldkamp; Deborah A Nickerson; Michael J Bamshad; Lawrence C Brody; Jennita Reefhuis
Journal:  Birth Defects Res       Date:  2019-07-21       Impact factor: 2.344

Review 7.  Humans, mice, and mechanisms of intestinal atresias: a window into understanding early intestinal development.

Authors:  Peter F Nichol; Amy Reeder; Robert Botham
Journal:  J Gastrointest Surg       Date:  2010-11-30       Impact factor: 3.452

8.  Fibroblast growth factor 10 represses premature cell differentiation during establishment of the intestinal progenitor niche.

Authors:  Pia Nyeng; Maureen Ann Bjerke; Gitte Anker Norgaard; Xiaoling Qu; Sune Kobberup; Jan Jensen
Journal:  Dev Biol       Date:  2010-09-27       Impact factor: 3.582

9.  Duodenal atresia associated with "apple peel" small bowel without deletion of fibroblast growth factor-10 or fibroblast growth factor receptor 2IIIb: report of a case.

Authors:  Yukihiro Tatekawa; Hiromichi Kanehiro; Yoshiyuki Nakajima
Journal:  Surg Today       Date:  2007-04-30       Impact factor: 2.549

10.  Formation of intestinal atresias in the Fgfr2IIIb-/- mice is not associated with defects in notochord development or alterations in Shh expression.

Authors:  Amy L Reeder; Robert A Botham; Marta Franco; Krzysztof M Zaremba; Peter F Nichol
Journal:  J Surg Res       Date:  2012-04-29       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.